|
Apr 1
|
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
|
|
Mar 31
|
Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 31
|
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
|
|
Mar 14
|
Biotech Alert: Searches spiking for these stocks today
|
|
Mar 12
|
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
|
|
Mar 10
|
Update: Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday
|
|
Feb 27
|
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
|
|
Feb 11
|
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
|
Feb 10
|
Mustang Bio Announces Closing of $8 Million Public Offering
|
|
Oct 9
|
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
|
|
Sep 4
|
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Sep 4
|
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Sep 4
|
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
|
Sep 3
|
Avenue Therapeutics to Participate in Upcoming Investor Conferences
|
|
Sep 2
|
Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock
|
|
Jul 25
|
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
|
|
Jul 25
|
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
|
|
Jun 24
|
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
|
|
Jun 21
|
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Jun 20
|
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
|